Amgen Inc. (NASDAQ:AMGN) Shares Sold by Eads & Heald Wealth Management

Eads & Heald Wealth Management reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,286 shares of the medical research company’s stock after selling 139 shares during the quarter. Amgen comprises approximately 1.3% of Eads & Heald Wealth Management’s portfolio, making the stock its 22nd largest holding. Eads & Heald Wealth Management’s holdings in Amgen were worth $2,674,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Moneta Group Investment Advisors LLC grew its position in Amgen by 83,875.6% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after purchasing an additional 7,532,031 shares during the last quarter. Norges Bank purchased a new position in Amgen during the 4th quarter worth $1,351,778,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Amgen by 158.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock valued at $774,791,000 after acquiring an additional 1,806,456 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Amgen in the fourth quarter valued at about $4,589,900,000. Finally, Morgan Stanley boosted its holdings in shares of Amgen by 12.9% in the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after acquiring an additional 1,523,665 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Down 0.7 %

Shares of NASDAQ:AMGN traded down $1.77 during trading on Monday, reaching $265.51. The stock had a trading volume of 1,731,820 shares, compared to its average volume of 2,883,643. The business has a fifty day moving average price of $280.76 and a 200-day moving average price of $281.55. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The stock has a market cap of $142.29 billion, a P/E ratio of 21.40, a PEG ratio of 2.53 and a beta of 0.58. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The business had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company’s revenue was up 19.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.09 earnings per share. As a group, analysts anticipate that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.39%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is presently 72.06%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on AMGN shares. Morgan Stanley lowered their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 7th. Raymond James started coverage on shares of Amgen in a report on Thursday, March 28th. They issued a “market perform” rating on the stock. StockNews.com downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. SVB Leerink downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $324.00 to $318.00 in a report on Wednesday, February 7th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $329.00 price objective on shares of Amgen in a report on Wednesday, April 3rd. Ten investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $295.30.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.